Diffuse Hypopigmentation Followed by
Hyperpigmentation in an African American Woman with Hemangiopericytoma
Treated with Dasatinib
Published: November 1, 2014 | DOI: https://doi.org/10.7860/JCDR/2014/.5160
Karim Boudadi, Rashmi Chugh
1. Clinical Lecturer, Division of General Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
2. Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Correspondence
Dr. Rashmi Chugh,
C407 Med Inn, SPC 5843, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-5843, USA.
E-mail : rashmim@umich.edu
Dasatinib is a second-generation multi-target tyrosine kinase inhibitor (TKI) that has activity against many imatinib-resistant BCR-ABL mutant forms, Src, and c-Kit tyrosine kinases. While skin hypopigmentation is a well recognized adverse effect of first generation TKIs; it has rarely been reported with dasatinib. We report a unique case of diffuse cutaneous hypopigmentation induced by dasatinib followed by hyperpigmentation occurring in the same patient. A 52-year-old African American female with a history of metastatic hemangiopericytoma was initiated on dasatinib as part of a clinical trial. After 2 months of treatment, she developed generalized skin hypopigmentation. Within 1 month of discontinuing the drug, the patient’s skin pigmentation returned to normal. However, she then developed diffuse skin hyperpig - mentation over the next couple of months. The hyperpigmentation was self-limited, and eventually resolved after several months.
[
FULL TEXT ] | [ PDF]